Parexel Biotech conducting Ph IIa neurodegenerative disease trial

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Zinkevych)
(Image: Getty/Zinkevych)

Related tags: Parexel Biotech, Clinical trial

AlzProtect is collaborating with Parexel Biotech to advance a Phase IIa clinical trial of its lead candidate, AZP2006, which is being developed for the treatment of a rare neurodegenerative disease.

Alzprotect is a biopharmaceutical company focused on developing drugs for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease.

Parexel Biotech today announced that it has been selected to conduct the clinical Ph IIa development of AZP2006, Alzprotect’s flagship product.

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted AZP2006 orphan drug status in the indication of PSP.

AZP2006 was previously tested in two Phase I trials and demonstrated excellent tolerability, with no adverse effects, according to the company.

Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.

The contract research organization (CRO) launched​ the dedicated biotech division earlier this year.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars